Natera Inc (NTRA) Shares Sold by MetLife Investment Advisors LLC
MetLife Investment Advisors LLC lessened its holdings in shares of Natera Inc (NASDAQ:NTRA) by 39.0% in the 4th quarter, Holdings Channel reports. The firm owned 13,813 shares of the medical research company’s stock after selling 8,840 shares during the quarter. MetLife Investment Advisors LLC’s holdings in Natera were worth $193,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Jennison Associates LLC lifted its position in shares of Natera by 1.8% during the 4th quarter. Jennison Associates LLC now owns 3,706,873 shares of the medical research company’s stock worth $51,748,000 after purchasing an additional 65,025 shares during the last quarter. Vanguard Group Inc lifted its position in shares of Natera by 28.9% during the 3rd quarter. Vanguard Group Inc now owns 3,612,860 shares of the medical research company’s stock worth $86,493,000 after purchasing an additional 808,976 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Natera by 28.9% during the 3rd quarter. Vanguard Group Inc. now owns 3,612,860 shares of the medical research company’s stock worth $86,493,000 after purchasing an additional 808,976 shares during the last quarter. BlackRock Inc. lifted its position in shares of Natera by 33.5% during the 3rd quarter. BlackRock Inc. now owns 2,785,208 shares of the medical research company’s stock worth $66,679,000 after purchasing an additional 698,379 shares during the last quarter. Finally, Macquarie Group Ltd. lifted its position in shares of Natera by 15.8% during the 3rd quarter. Macquarie Group Ltd. now owns 1,985,578 shares of the medical research company’s stock worth $47,535,000 after purchasing an additional 270,692 shares during the last quarter. 87.76% of the stock is owned by institutional investors and hedge funds.
In other Natera news, insider Matthew Rabinowitz sold 5,672 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $16.00, for a total value of $90,752.00. Following the completion of the transaction, the insider now owns 1,288,853 shares of the company’s stock, valued at approximately $20,621,648. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Jonathan Sheena sold 2,620 shares of the company’s stock in a transaction that occurred on Friday, March 29th. The shares were sold at an average price of $20.50, for a total value of $53,710.00. Following the completion of the sale, the insider now owns 240,390 shares in the company, valued at $4,927,995. The disclosure for this sale can be found here. In the last ninety days, insiders sold 351,313 shares of company stock valued at $7,132,873. Insiders own 13.18% of the company’s stock.
Natera stock opened at $18.54 on Monday. The company has a quick ratio of 1.99, a current ratio of 2.11 and a debt-to-equity ratio of 2.28. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of -8.62 and a beta of 1.89. Natera Inc has a 12 month low of $10.77 and a 12 month high of $29.62.
Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Tuesday, March 12th. The medical research company reported ($0.51) EPS for the quarter, meeting the consensus estimate of ($0.51). The firm had revenue of $67.00 million during the quarter, compared to analysts’ expectations of $62.87 million. Natera had a negative return on equity of 790.13% and a negative net margin of 49.72%. As a group, analysts expect that Natera Inc will post -2.24 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.watchlistnews.com/natera-inc-ntra-shares-sold-by-metlife-investment-advisors-llc/2980700.html.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Story: What is the Rule of 72?
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera Inc (NASDAQ:NTRA).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.